Hoth Therapeutics, Inc. (HOTH) Tuesday announced positive preclinical results for HT-KIT, a novel targeted therapy for gastrointestinal stromal tumors (GIST).
GIST is a rare but aggressive cancer often driven by activating mutations in the KIT receptor. Results from the study showed that HT-KIT effectively reduced KIT receptor expression within 24 hours, with effects sustained for 72 hours. Further, HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment.
"By directly targeting the underlying genetic drivers of GIST, HT-KIT has the potential to overcome limitations of existing therapies and provide a new therapeutic strategy for patients with KIT-driven malignancies," said Robb Knie, CEO of Hoth Therapeutics.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.